Quantinno Capital Management LP Raises Holdings in Pfizer Inc. $PFE

Quantinno Capital Management LP lifted its position in Pfizer Inc. (NYSE:PFE) by 10.4% during the 1st quarter, HoldingsChannel reports. The firm owned 1,855,826 shares of the biopharmaceutical company’s stock after acquiring an additional 175,560 shares during the quarter. Quantinno Capital Management LP’s holdings in Pfizer were worth $52,112,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. increased its stake in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer during the 4th quarter valued at approximately $26,000. YANKCOM Partnership purchased a new position in shares of Pfizer in the fourth quarter valued at $28,000. HFM Investment Advisors LLC increased its position in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Global Trust Asset Management LLC raised its stake in Pfizer by 126.7% during the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 650 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The European Commission granted marketing authorization for Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for the 2026–2027 season. The approval supports continued seasonal vaccine revenue, although demand remains difficult to forecast. BioNTech and Pfizer Secure EU Approval for XFG-Adapted COVID-19 Vaccine for 2026-2027 Season
• Positive Sentiment: Québec selected Pfizer’s PREVNAR 20 for its publicly funded pediatric pneumococcal immunization program. The decision could expand vaccine adoption and provide recurring sales support in the Canadian market. Pfizer’s PREVNAR 20 Selected for Québec’s Publicly Funded Pediatric Pneumococcal Immunization Program
• Positive Sentiment: Erste Group Bank raised its fiscal 2027 Pfizer earnings estimate to $2.86 per share from $2.84. The increase, though modest, signals slightly improved confidence in the company’s future earnings trajectory. Pfizer FY2027 Earnings Estimate Update
• Neutral Sentiment: Pfizer completed a Phase 1 study evaluating formulation and dosing for ibuzatrelvir, an oral antiviral candidate. The update advances development but offers no evidence yet of efficacy or commercial approval. Pfizer Fine Tunes Ibuzatrelvir Tablet in Completed Phase 1 Study
• Neutral Sentiment: Analysts expect Pfizer to potentially beat second-quarter earnings estimates, supported by key products and cost or operational improvements. Investors are focused on whether management maintains its full-year 2026 earnings guidance of $2.80–$3.00 per share and addresses COVID-related revenue declines. Pfizer Expected to Beat Earnings Estimates
• Negative Sentiment: Investors remain cautious ahead of the earnings release because Pfizer must offset declining COVID-related sales and demonstrate progress in cancer, obesity and other growth areas. Uncertainty around guidance and the pace of its business reset may be limiting buying interest.

Analyst Ratings Changes

PFE has been the subject of a number of recent research reports. Citigroup lifted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. BMO Capital Markets reduced their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Finally, Morgan Stanley lifted their target price on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.50.

Pfizer Stock Down 0.4%

Shares of NYSE:PFE opened at $25.16 on Thursday. The firm has a market capitalization of $143.40 billion, a PE ratio of 19.21 and a beta of 0.35. The business has a 50 day simple moving average of $25.08 and a two-hundred day simple moving average of $26.16. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same period last year, the company earned $0.92 EPS. Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.